Soliris is administered intravenously to treat patients suffering from a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH) which destroys red blood cells and leads to blood clotting. Soliris helps reduce hemolysis in patients which results in reduced symptoms and overall health leading to a better quality of life.

At least two weeks prior to receiving treatment, the patient must be vaccinated against meningococcal infection.

See all infusion medications